Author: Xiong, Ya-jie; Song, Yun-zhen; Zhu, Ying; Zuo, Wen-qing; Zhao, Yi-fan; Shen, Xiao; Wang, Wen-juan; Liu, Ya-li; Wu, Jun-chao; Liang, Zhong-qin
Title: Neuroprotective effects of olanzapine against rotenone-induced toxicity in PC12 cells Cord-id: 1v51s9ql Document date: 2020_3_2
ID: 1v51s9ql
Snippet: Olanzapine is an antipsychotic drug used to treat patients with schizophrenia due to its lower incidence of extrapyramidal symptoms. Previous studies have shown that olanzapine activates AMP-activated protein kinase (AMPK), and induce autophagy in SH-SY5Y cell line. In this study, we investigated whether olanzapine protected against rotenone-induced neurotoxicity in PC12 cells. We showed that treatment with olanzapine increased the phosphorylation of AMPK in both dose- and time-dependent manners
Document: Olanzapine is an antipsychotic drug used to treat patients with schizophrenia due to its lower incidence of extrapyramidal symptoms. Previous studies have shown that olanzapine activates AMP-activated protein kinase (AMPK), and induce autophagy in SH-SY5Y cell line. In this study, we investigated whether olanzapine protected against rotenone-induced neurotoxicity in PC12 cells. We showed that treatment with olanzapine increased the phosphorylation of AMPK in both dose- and time-dependent manners in PC12 cells. In addition, olanzapine activated autophagy and increased autophagic vacuoles. Furthermore, olanzapine pretreatment could protect PC12 cells from rotenone-induced apoptosis. Besides, olanzapine pretreatment could suppress the rotenone-induced depolarization of mitochondrial potential and thus protect the cells. Moreover, pretreatment with specific AMPK inhibitor compound C or with autophagy inhibitor 3-methyladenine impaired the protective effect of olanzapine on rotenone-treated PC12 cells. In summary, our results show for the first time that olanzapine ameliorates rotenone-induced injury by activating autophagy through AMPK pathway.
Search related documents:
Co phrase search for related documents- absence presence and acute setting: 1
- absence presence and low incidence: 1, 2
- absence presence and lysis buffer: 1, 2, 3, 4, 5
- active site and adp ribose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- active site and adp ribose parp polymerase: 1
- acute setting and low incidence: 1
- lysate protein concentration and lysis buffer: 1
Co phrase search for related documents, hyperlinks ordered by date